Sara A Lorkiewicz1, Alicia S Ventura2,3, Timothy C Heeren4, Michael R Winter5, Alexander Y Walley3, Meg Sullivan6, Jeffrey H Samet2,3, Richard Saitz2,3. 1. a Graduate Medical Sciences, Boston University School of Medicine , Boston , Massachusetts , USA. 2. b Department of Community Health Sciences , Boston University School of Public Health , Boston , Massachusetts , USA. 3. e Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine , Department of Medicine, Boston University School of Medicine and Boston Medical Center , Boston , Massachusetts , USA. 4. c Department of Biostatistics , Boston University School of Public Health , Boston , Massachusetts , USA. 5. d Data Coordinating Center , Boston University School of Public Health , Boston , Massachusetts , USA. 6. f Section of Infectious Diseases , Department of Medicine, Boston University School of Medicine and Boston Medical Center , Boston , Massachusetts , USA.
Abstract
BACKGROUND: Substance use is common among people with human immunodeficiency virus (HIV) infection. Alcohol, marijuana, and HIV can have negative effects on cognition. Associations between current and lifetime marijuana and alcohol use and cognitive dysfunction in people with HIV infection were examined. METHODS: Some 215 HIV-infected adults with Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) substance dependence or ever injection drug use were studied. In adjusted cross-sectional regression analyses associations were assessed between current marijuana use, current heavy alcohol use, lifetime marijuana use, lifetime alcohol use, duration of heavy alcohol use (the independent variables), and 3 measures of cognitive dysfunction (dependent variables): both the (i) memory and (ii) attention domains from the Montreal Cognitive Assessment (MoCA) and the (iii) 4-item cognitive function scale (CF4) from the Medical Outcomes Study HIV Health Survey (MOS-HIV). Analyses were adjusted for demographics, primary language, depressive symptoms, anxiety, comorbidities, antiretroviral therapy, hepatitis C virus (ever), duration of HIV infection (years), HIV-viral load (log copies/mL), CD4 cell count, lifetime and recent cocaine use, and recent illicit and prescribed opioid use. RESULTS: Current marijuana use was significantly and negatively associated with the MOS-HIV CF4 score (adjusted mean difference = -0.40, P = .01). Current marijuana use was not significantly associated with either MoCA score. Lifetime marijuana use and current heavy and lifetime alcohol use and duration of heavy alcohol use were not associated with any measure of cognitive dysfunction. CONCLUSION: Current marijuana use was associated with one measure of cognitive dysfunction, but there was not a consistent pattern of association with lifetime marijuana use or alcohol use and measures of cognitive dysfunction. Understanding the mechanism by which marijuana, with and without alcohol, are associated with worse cognition warrants larger, longer studies with more precise and diverse measurements of cognitive function.
BACKGROUND: Substance use is common among people with human immunodeficiency virus (HIV) infection. Alcohol, marijuana, and HIV can have negative effects on cognition. Associations between current and lifetime marijuana and alcohol use and cognitive dysfunction in people with HIV infection were examined. METHODS: Some 215 HIV-infected adults with Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) substance dependence or ever injection drug use were studied. In adjusted cross-sectional regression analyses associations were assessed between current marijuana use, current heavy alcohol use, lifetime marijuana use, lifetime alcohol use, duration of heavy alcohol use (the independent variables), and 3 measures of cognitive dysfunction (dependent variables): both the (i) memory and (ii) attention domains from the Montreal Cognitive Assessment (MoCA) and the (iii) 4-item cognitive function scale (CF4) from the Medical Outcomes Study HIV Health Survey (MOS-HIV). Analyses were adjusted for demographics, primary language, depressive symptoms, anxiety, comorbidities, antiretroviral therapy, hepatitis C virus (ever), duration of HIV infection (years), HIV-viral load (log copies/mL), CD4 cell count, lifetime and recent cocaine use, and recent illicit and prescribed opioid use. RESULTS: Current marijuana use was significantly and negatively associated with the MOS-HIV CF4 score (adjusted mean difference = -0.40, P = .01). Current marijuana use was not significantly associated with either MoCA score. Lifetime marijuana use and current heavy and lifetime alcohol use and duration of heavy alcohol use were not associated with any measure of cognitive dysfunction. CONCLUSION: Current marijuana use was associated with one measure of cognitive dysfunction, but there was not a consistent pattern of association with lifetime marijuana use or alcohol use and measures of cognitive dysfunction. Understanding the mechanism by which marijuana, with and without alcohol, are associated with worse cognition warrants larger, longer studies with more precise and diverse measurements of cognitive function.
Entities:
Keywords:
Alcohol; HIV infection; cannabis; cognitive function; ethanol; lifetime; marijuana
Authors: Sapna M Patel; April D Thames; Natalie Arbid; Stella E Panos; Steven Castellon; Charles H Hinkin Journal: J Clin Exp Neuropsychol Date: 2013-04-03 Impact factor: 2.475
Authors: Reto Auer; Eric Vittinghoff; Kristine Yaffe; Arnaud Künzi; Stefan G Kertesz; Deborah A Levine; Emiliano Albanese; Rachel A Whitmer; David R Jacobs; Stephen Sidney; M Maria Glymour; Mark J Pletcher Journal: JAMA Intern Med Date: 2016-03 Impact factor: 44.409
Authors: Sheri L Towe; Christina S Meade; Christine C Cloak; Ryan P Bell; Julian Baptiste; Linda Chang Journal: J Neuroimmune Pharmacol Date: 2020-05-22 Impact factor: 4.147
Authors: Cecilia T Costiniuk; Zahra Saneei; Syim Salahuddin; Joseph Cox; Jean-Pierre Routy; Sergio Rueda; Sara J Abdallah; Dennis Jensen; Bertrand Lebouché; Marie-Josée Brouillette; Marina Klein; Jason Szabo; Charles Frenette; Andreas Giannakis; Mohammad-Ali Jenabian Journal: Cannabis Cannabinoid Res Date: 2019-09-23
Authors: Chukwuemeka N Okafor; Michael W Plankey; Michael Li; Xinguang Chen; Pamela J Surkan; Steve Shoptaw; Eileen Martin; Ronald Cohen; Ned Sacktor; Robert L Cook Journal: Subst Use Misuse Date: 2019-01-30 Impact factor: 2.164
Authors: Nicholas J Christopher-Hayes; Brandon J Lew; Alex I Wiesman; Mikki Schantell; Jennifer O'Neill; Pamela E May; Susan Swindells; Tony W Wilson Journal: Hum Brain Mapp Date: 2021-08-31 Impact factor: 5.038